Edition:
United States

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

1.46USD
2:44pm EST
Change (% chg)

$-0.04 (-2.67%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.50
Day's Low
$1.44
Volume
29,613
Avg. Vol
68,379
52-wk High
$16.96
52-wk Low
$1.21

Select another date:

Mon, Dec 11 2017

BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA

BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock

* Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ Source text: (http://bit.ly/2mmbjHr) Further company coverage:

BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS

BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma

* Armistice Capital, Llc reports 5.6 percent passive stake in Anthera Pharmaceuticals Inc as on October 24, 2017 - SEC filing‍​ Source text: (http://bit.ly/2A4C2Kr) Further company coverage:

BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering

* Anthera Pharmaceuticals announces pricing of $15 million private placement offering

BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

* Anthera Pharmaceuticals surpasses 50% milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

BRIEF-Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

* Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

BRIEF-FDA grants orphan status to Anthera's kidney disease drug

* Anthera announces FDA orphan drug designation for blisibimod for the treatment of iga nephropathy

BRIEF-Anthera Pharmaceuticals reports Q2 earnings per share $0.03

* Anthera Pharmaceuticals provides business update and reports 2017 second quarter financial results

Select another date: